- Axonics Modulation Technologies Inc (NASDAQ: AXNX) has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence.
- The transaction includes a total consideration of $200 million in cash and stock, along with a potential future milestone of $35 million.
- Bulkamid is a homogenous non-particulate hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure for restoring the urethra’s natural closing pressure.
- The hydrogel secured CE Mark approval in 2003 and the FDA approval last year.
- Price Action: AXNX shares are 1.34% higher at $51.50 in the premarket session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
